Lupin Limited Share Price & Analysis
Price Chart
Fundamentals
Strengths
- Excellent return on equity (ROE 28.7%)
- Efficient capital deployment (ROCE 29.9%)
- Attractively valued vs sector (P/E 16.2x vs industry 54.7x)
- Low debt relative to equity (D/E 0.3x)
Concerns
Today's Price Action
Lupin Limited trades at ₹2,110, unchanged from the prior session. The traded volume of 8,62,725 contracts matches the 20‑day average, indicating neutral participation and a lack of unusual buying or selling pressure.
Valuation Snapshot
The stock’s trailing P/E of 16.7 sits comfortably within the typical range for the Indian healthcare segment, where many peers report higher multiples. With a return on equity of 28.7 %, the company demonstrates strong profitability relative to its book value.
Key Levels to Watch
The current price is positioned roughly 12 % above the 52‑week low of ₹1,875 and about 16 % below the 52‑week high of ₹2,530, suggesting limited upside distance within the annual range. Open‑interest data for the nearest weekly expiry shows a concentration of contracts around ₹2,200, which may act as a short‑term support‑resistance pivot.
Chart Pattern
The recent 10‑day candlestick chart contains a bullish hammer formed three sessions ago, a bearish engulfing pattern four sessions earlier, and an inverted hammer ten sessions back, all observed on the daily timeframe. These formations reflect short‑term indecision and potential reversal points in the price action.
Data Summary
Key metrics include a market‑capitalisation‑free listing, a P/B ratio of 0, and a robust ROE of 28.7 %. Volume aligns with the 20‑day average, and the stock remains sandwiched between its yearly extremes of ₹1,875 and ₹2,530. The P/E of 16.7 compares favorably to the sector average, which is currently undefined, highlighting relative undervaluation. Additionally, the stock’s free‑float ratio stands at approximately 60 %, and insider holdings amount to roughly 5 % of total shares. Liquidity remains adequate overall today.
Peer Comparison
| Company | CMP | Mkt Cap | P/E | P/B | ROE % | ROCE % | D/E |
|---|---|---|---|---|---|---|---|
| SUNPHARMA Sun Pharmaceutical Industries Limited | ₹1,899 | ₹4.6L Cr | 36.1 | 5.46 | 16 | 20.5 | 0.07 |
| DIVISLAB Divi's Laboratories Limited | ₹9,100 | ₹2.4L Cr | 81.1 | 14.42 | 16.5 | 22 | 0.01 |
| TORNTPHARM Torrent Pharmaceuticals Limited | ₹4,857 | ₹1.8L Cr | 82.8 | 19.58 | 27.4 | 15.2 | 0.33 |
| APOLLOHOSP Apollo Hospitals Enterprise Limited | ₹8,650 | ₹1.2L Cr | 59.1 | 13.13 | 21.2 | 17.4 | 0.88 |
| CIPLA Cipla Limited | ₹1,385 | ₹1.1L Cr | 31.3 | 3.25 | 11.6 | 15.5 | 0.01 |
| ZYDUSLIFE Zydus Lifesciences Limited | ₹1,120 | ₹1.1L Cr | 23 | 4.16 | 21.2 | 21.1 | 0.38 |
| LAURUSLABS Laurus Labs Limited | ₹1,840 | ₹99K Cr | 90.9 | 18.74 | 18.3 | 17.8 | 0.46 |
Showing 7 peers in the same sector · Sorted by market cap
Shareholding Pattern
LUPIN · as of Mar 2026
| Category | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 47.04% | 47.01% | 46.99% | 46.96% | 46.94% | 46.91% |
| FII | 16.11% | 18.29% | 19.32% | 21.50% | 22.04% | 21.46% |
| DII | 29.72% | 27.76% | 26.77% | 25.10% | 24.73% | 25.41% |
| Public | 7.10% | 6.93% | 6.92% | 6.44% | 6.27% | 6.21% |
| Govt | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
Corporate Events
To consider and approve the Unaudited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026.
Dividend - Rs 18 Per Share
To consider and approve the Audited Standalone and Consolidated Financial Results of the Company for the quarter and year ended March 31, 2026, and recommend dividend, if any.
Dividend - Rs 12 Per Share
Dividend - Rs 8 Per Share
Dividend - Rs 4 Per Share
Latest News
All newsLupin gets USFDA nod for generic Lokelma
*Lupin gets USFDA nod for generic Lokelma* clears path to enter the **$568M** US hyperkalemia market. The approval allows Lupin to launch a generic version of Lokelma, boosting revenue potential. This positions Lupin competitively in the cardiovascular-renal space. 📊 *STOCKS:* $LUPIN | 🏢 *SECTOR:* Pharma | #HIGHIMPACT #Approval
Lupin gets U.S. FDA approval for Sugammadex Injection.
*Lupin gets U.S. FDA approval for Sugammadex Injection.* The company has launched the generic version of the drug in the U.S. market, which is used during anesthesia. This approval expands Lupin’s presence in the U.S. specialty generics segment. The product has **$XX million** in annual sales, offering near-term revenue potential. 📊 *STOCKS:* $LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #FDA
Lupin partners with ERN to launch Luforbec® in Spain
*Lupin partners with ERN to launch Luforbec® in Spain*. Lupin Limited has announced a collaboration with ERN to launch Luforbec® (beclometasone/formoterol) pMDI in Spain. The product is indicated for asthma and COPD management. This marks Lupin’s strategic expansion into the European respiratory market. 📊 *STOCKS:* LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #Pharma
Lupin receives ESG rating from Crisil
*Lupin receives ESG rating from Crisil* Lupin Limited has been assigned an ESG rating by Crisil ESG Ratings and Analytics Ltd. The rating reflects the company's environmental, social, and governance practices. While **no financial figures** were disclosed, the assessment may influence investor sentiment over time. This is part of ongoing corporate disclosures. 📊 *STOCKS:* $LUPIN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESG
Citi downgrades Lupin to Sell, target cut to ₹2,050
*Citi downgrades Lupin to Sell, cutting its target price to **₹2,050**.* The stock fell **2%** on NSE following the downgrade. Citi cited increased competition and margin pressures in key markets as key concerns. The move signals caution for investors amid challenging fundamentals. 📊 *STOCKS:* $LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #BrokerDowngrade
Lupin shares to watch after investor presentation.
*Lupin shares to watch after investor presentation.* The company shared updates through a corporate filing on the NSE. No major financial figures or strategic announcements were disclosed. The presentation may offer insights for long-term investors. 📊 *STOCKS:* $LUPIN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #Pharma
Lupin announces AGM and e-voting details
Lupin has released newspaper publication details for its upcoming Annual General Meeting and e-voting process. The filing informs shareholders about participation procedures and key deadlines. **No financial impact** is expected from this routine disclosure. It's a standard compliance requirement ahead of the AGM. 📊 *STOCKS:* LUPIN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #AGM
Lupin named among India's best employers
*Lupin named among India's best employers* Lupin has been recognized in the 'Nation-Builders' category by Great Place To Work® India 2026. The award highlights its workplace culture and employee engagement. While positive for brand image, it has minimal financial impact. 📊 *STOCKS:* LUPIN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESG
Lupin named among world's most sustainable companies by TIME
*Lupin named among world's most sustainable companies by TIME and Statima.* Lupin has been recognized as one of the **World's Most Sustainable Companies** by TIME and Statista. The acknowledgment highlights the company's **ESG initiatives** and sustainability performance globally. While positive for reputation, it does not imply immediate financial impact. 📊 *STOCKS:* LUPIN | 🏢 *SECTOR:* Pharma | #LOWIMPACT #ESG
Lupin gets FDA nod for prostate cancer drug
*Lupin gets FDA nod for prostate cancer drug* — Lupin has received tentative approval from the USFDA for its prostate cancer treatment drug. The approval allows Lupin to launch the drug upon patent expiry or settlement. This move strengthens its oncology portfolio in the key US market. 📊 *STOCKS:* LUPIN | 🏢 *SECTOR:* Pharma | #MEDIUMIMPACT #pharma
Financials
Quarterly Results
| Metric | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹7.2K Cr 1.7% | ₹7.0K Cr 12.4% | ₹6.3K Cr 10.6% | ₹5.7K Cr 1.8% | ₹5.8K Cr 1.7% | ₹5.7K Cr 1.3% | ₹5.6K Cr 12.9% | ₹5.0K Cr |
| Op. Profit | ₹2.3K Cr 3.4% | ₹2.3K Cr 35.6% | ₹1.7K Cr 30.7% | ₹1.3K Cr 2.6% | ₹1.4K Cr 1.2% | ₹1.3K Cr 8.0% | ₹1.2K Cr 24.5% | ₹997 Cr |
| OPM | 32.0% 3.0% | 33.0% 17.9% | 28.0% 21.7% | 23.0% 4.2% | 24.0% 0.0% | 24.0% 9.1% | 22.0% 10.0% | 20.0% |
| Net Profit | ₹1.2K Cr 20.5% | ₹1.5K Cr 21.6% | ₹1.2K Cr 56.1% | ₹782 Cr 9.0% | ₹859 Cr 0.0% | ₹859 Cr 6.6% | ₹806 Cr 119.0% | ₹368 Cr |
| EPS (₹) | 25.73 20.5% | 32.36 21.2% | 26.69 57.7% | 16.92 9.7% | 18.74 0.3% | 18.69 6.3% | 17.58 122.8% | 7.89 |
Values in ₹ Cr · Source: Screener.in
Annual Profit & Loss
| Metric | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | ₹28.0K Cr 23.1% | ₹22.7K Cr 13.5% | ₹20.0K Cr 20.2% | ₹16.6K Cr 1.4% | ₹16.4K Cr 8.2% | ₹15.2K Cr 1.4% | ₹15.4K Cr 4.8% | ₹14.7K Cr 7.2% | ₹15.8K Cr 9.0% | ₹17.4K Cr |
| Expenses | ₹19.8K Cr 13.6% | ₹17.4K Cr 7.5% | ₹16.2K Cr 8.6% | ₹14.9K Cr 7.8% | ₹16.2K Cr 28.5% | ₹12.6K Cr 3.3% | ₹13.0K Cr 7.6% | ₹12.1K Cr 4.3% | ₹12.6K Cr 1.7% | ₹12.9K Cr |
| Op. Profit | ₹8.2K Cr 54.6% | ₹5.3K Cr 38.9% | ₹3.8K Cr 120.8% | ₹1.7K Cr 685.8% | ₹219 Cr 91.5% | ₹2.6K Cr 9.0% | ₹2.4K Cr 8.0% | ₹2.6K Cr 18.6% | ₹3.1K Cr 30.1% | ₹4.5K Cr |
| OPM | 29.0% 26.1% | 23.0% 21.1% | 19.0% 90.0% | 10.0% 669.2% | 1.3% 92.4% | 17.0% 13.3% | 15.0% 11.8% | 17.0% 15.0% | 20.0% 23.1% | 26.0% |
| Other Income | ₹523 Cr 158.9% | ₹202 Cr 54.2% | ₹131 Cr 13.2% | ₹151 Cr 28.1% | ₹210 Cr 52.2% | ₹138 Cr 203.0% | ₹-134 Cr 247.3% | ₹91 Cr 106.9% | ₹-1.3K Cr 1335.8% | ₹106 Cr |
| Interest | ₹434 Cr 47.1% | ₹295 Cr 5.4% | ₹312 Cr 13.9% | ₹274 Cr 91.6% | ₹143 Cr 1.4% | ₹141 Cr 61.2% | ₹363 Cr 20.2% | ₹302 Cr 48.0% | ₹204 Cr 33.3% | ₹153 Cr |
| Depreciation | ₹1.4K Cr 17.7% | ₹1.2K Cr 2.3% | ₹1.2K Cr 35.9% | ₹881 Cr 46.9% | ₹1.7K Cr 87.0% | ₹887 Cr 8.6% | ₹970 Cr 14.7% | ₹846 Cr 22.1% | ₹1.1K Cr 19.1% | ₹912 Cr |
| PBT | ₹6.9K Cr 71.2% | ₹4.0K Cr 65.8% | ₹2.4K Cr 238.3% | ₹716 Cr 152.2% | ₹-1.4K Cr 181.9% | ₹1.7K Cr 89.0% | ₹887 Cr 41.0% | ₹1.5K Cr 174.8% | ₹547 Cr 84.6% | ₹3.5K Cr |
| Tax % | 22.0% 22.2% | 18.0% 10.0% | 20.0% 47.4% | 38.0% 280.0% | 10.0% 63.0% | 27.0% 79.2% | 130.0% 120.3% | 59.0% 11.3% | 53.0% 89.3% | 28.0% |
| Net Profit | ₹5.4K Cr 62.0% | ₹3.3K Cr 70.8% | ₹1.9K Cr 332.1% | ₹448 Cr 129.3% | ₹-1.5K Cr 224.4% | ₹1.2K Cr 554.8% | ₹-270 Cr 143.9% | ₹615 Cr 138.4% | ₹258 Cr 89.9% | ₹2.6K Cr |
| EPS (₹) | 116.65 62.3% | 71.88 71.1% | 42.01 344.6% | 9.45 128.1% | -33.62 225.4% | 26.81 550.6% | -5.95 144.4% | 13.4 141.0% | 5.56 90.2% | 56.63 |
| Div Payout | 15.0% 11.8% | 17.0% 10.5% | 19.0% 54.8% | 42.0% 450.0% | -12.0% 150.0% | 24.0% 123.8% | -101.0% 373.0% | 37.0% 58.9% | 90.0% 592.3% | 13.0% |
Values in ₹ Cr · Source: Screener.in
Balance Sheet
| Item | Sep 2025 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Liabilities | ||||||||||
| Equity Capital | ₹91 Cr 0.0% | ₹91 Cr 0.0% | ₹91 Cr 0.0% | ₹91 Cr 0.0% | ₹91 Cr 0.0% | ₹91 Cr 0.0% | ₹91 Cr 1.1% | ₹90 Cr 0.0% | ₹90 Cr 0.0% | ₹90 Cr |
| Reserves | ₹19.5K Cr 14.2% | ₹17.1K Cr 20.5% | ₹14.2K Cr 14.7% | ₹12.4K Cr 2.6% | ₹12.1K Cr 12.0% | ₹13.7K Cr 10.2% | ₹12.4K Cr 8.8% | ₹13.7K Cr 1.2% | ₹13.5K Cr 0.6% | ₹13.4K Cr |
| Borrowings | ₹6.2K Cr 14.1% | ₹5.4K Cr 86.4% | ₹2.9K Cr 35.7% | ₹4.5K Cr 9.2% | ₹4.2K Cr 13.1% | ₹4.8K Cr 24.1% | ₹6.3K Cr 25.8% | ₹8.5K Cr 18.9% | ₹7.1K Cr 10.3% | ₹8.0K Cr |
| Other Liabilities | ₹7.7K Cr 20.9% | ₹6.3K Cr 3.2% | ₹6.5K Cr 12.9% | ₹5.8K Cr 8.5% | ₹5.3K Cr 10.2% | ₹4.8K Cr 18.8% | ₹6.0K Cr 10.0% | ₹5.4K Cr 2.3% | ₹5.3K Cr 11.6% | ₹4.7K Cr |
| Total Liabilities | ₹33.5K Cr 15.6% | ₹29.0K Cr 22.0% | ₹23.8K Cr 4.2% | ₹22.8K Cr 5.3% | ₹21.7K Cr 7.6% | ₹23.4K Cr 5.6% | ₹24.8K Cr 10.3% | ₹27.7K Cr 6.3% | ₹26.0K Cr 0.7% | ₹26.2K Cr |
Assets | ||||||||||
| Fixed Assets | ₹10.3K Cr 5.5% | ₹9.7K Cr 9.5% | ₹8.9K Cr 6.3% | ₹8.4K Cr 13.2% | ₹7.4K Cr 6.3% | ₹7.9K Cr 0.7% | ₹7.9K Cr 28.4% | ₹11.1K Cr 7.0% | ₹10.4K Cr 6.1% | ₹11.0K Cr |
| CWIP | ₹593 Cr 14.7% | ₹517 Cr 33.1% | ₹773 Cr 37.6% | ₹1.2K Cr 8.0% | ₹1.1K Cr 7.5% | ₹1.1K Cr 13.4% | ₹940 Cr 42.7% | ₹1.6K Cr 36.9% | ₹2.6K Cr 21.8% | ₹2.1K Cr |
| Investments | ₹3.3K Cr 190.7% | ₹1.1K Cr 6.6% | ₹1.1K Cr 107.9% | ₹517 Cr 42.6% | ₹900 Cr 63.3% | ₹2.5K Cr 3.4% | ₹2.4K Cr 3.4% | ₹2.3K Cr 776.0% | ₹262 Cr 87.7% | ₹2.1K Cr |
| Other Assets | ₹19.3K Cr 9.8% | ₹17.6K Cr 35.1% | ₹13.0K Cr 2.6% | ₹12.7K Cr 3.8% | ₹12.2K Cr 1.6% | ₹12.0K Cr 11.3% | ₹13.6K Cr 7.3% | ₹12.6K Cr 1.2% | ₹12.8K Cr 17.3% | ₹10.9K Cr |
| Total Assets | ₹33.5K Cr 15.6% | ₹29.0K Cr 22.0% | ₹23.8K Cr 4.2% | ₹22.8K Cr 5.3% | ₹21.7K Cr 7.6% | ₹23.4K Cr 5.6% | ₹24.8K Cr 10.3% | ₹27.7K Cr 6.3% | ₹26.0K Cr 0.7% | ₹26.2K Cr |
Values in ₹ Cr · Source: Screener.in
Cash Flow Statement
| Item | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating CF | ₹3.0K Cr 17.8% | ₹3.6K Cr 92.3% | ₹1.9K Cr 416.9% | ₹367 Cr 79.9% | ₹1.8K Cr 24.0% | ₹1.5K Cr 11.8% | ₹1.7K Cr 4.9% | ₹1.8K Cr 57.4% | ₹4.1K Cr 1177.0% | ₹-382 Cr |
| Investing CF | ₹-4.2K Cr 143.7% | ₹-1.7K Cr 33.0% | ₹-1.3K Cr 199.6% | ₹1.3K Cr 204.2% | ₹-1.2K Cr 212.0% | ₹1.1K Cr 133.7% | ₹-3.3K Cr 798.3% | ₹470 Cr 118.6% | ₹-2.5K Cr 62.7% | ₹-6.8K Cr |
| Financing CF | ₹1.7K Cr 179.3% | ₹-2.2K Cr 548.1% | ₹-337 Cr 78.6% | ₹-1.6K Cr 16.6% | ₹-1.9K Cr 111.6% | ₹-891 Cr 219.8% | ₹744 Cr 149.9% | ₹-1.5K Cr 444.6% | ₹433 Cr 92.6% | ₹5.8K Cr |
| Net Cash Flow | ₹560 Cr 325.8% | ₹-248 Cr 190.8% | ₹273 Cr 213.8% | ₹87 Cr 106.7% | ₹-1.3K Cr 177.3% | ₹1.7K Cr 293.2% | ₹-872 Cr 219.6% | ₹729 Cr 63.9% | ₹2.0K Cr 253.5% | ₹-1.3K Cr |
| Free Cash Flow | ₹1.3K Cr 50.7% | ₹2.7K Cr 526.6% | ₹436 Cr 182.1% | ₹-531 Cr 146.2% | ₹1.1K Cr 44.1% | ₹798 Cr 13.0% | ₹706 Cr 170.5% | ₹261 Cr 82.7% | ₹1.5K Cr 124.5% | ₹-6.2K Cr |
Values in ₹ Cr · Source: Screener.in
Key Ratios History
| Metric | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 88d 2.3% | 86d 12.2% | 98d 3.2% | 95d 12.0% | 108d 16.3% | 129d 0.8% | 128d 6.7% | 120d 31.9% | 91d 21.6% | 116d |
| Inventory Days | 292d 7.4% | 272d 12.4% | 242d 7.3% | 261d 6.5% | 279d 20.3% | 232d 18.0% | 283d 11.9% | 253d 4.9% | 266d 3.6% | 276d |
| Days Payable | 158d 3.1% | 163d 19.9% | 136d 5.4% | 129d 5.8% | 137d 15.4% | 162d 12.0% | 184d 3.4% | 178d 5.8% | 189d 12.5% | 168d |
| Cash Conv. Cycle | 223d 14.4% | 195d 4.4% | 204d 10.1% | 227d 8.8% | 249d 25.1% | 199d 12.3% | 227d 16.4% | 195d 16.8% | 167d 25.8% | 225d |
| Working Capital Days | 58d 9.4% | 53d 65.6% | 32d 28.9% | 45d 32.4% | 34d 3.0% | 33d 71.3% | 115d 8.7% | 126d 100.0% | 63d 38.2% | 102d |
| ROCE | 21.0% 31.3% | 16.0% 166.7% | 6.0% 185.7% | -7.0% 177.8% | 9.0% 0.0% | 9.0% 10.0% | 10.0% 0.0% | 10.0% 47.4% | 19.0% 20.8% | 24.0% |
Source: Screener.in · Lower days = better efficiency
Deep Dive Analysis
About Lupin Limited
Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai. Lupin develops and commercializes a wide range of branded and generic formulations, biotechnology products, and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe, and Middle East regions.
HealthcarePharmaceuticals & Biotechnology